二甲双胍联合吉西他滨治疗晚期胰腺癌疗效观察

Efficacy of metformin combined with gemcitabine in the treatment of advanced pancreatic cancer

目的探讨二甲双胍联合吉西他滨治疗晚期胰腺癌的临床疗效。方法选取2012年1月至2017年10月间江苏省无锡市第二人民医院收治的63例晚期胰腺癌患者,采用二甲双胍联合吉西他滨或联合吉西他滨+顺铂(GP方案)治疗的31例患者纳入试验组,采用吉西他滨或GP方案治疗的32例患者纳入对照组。比较两组患者的近期疗效、治疗不良反应、疾病无进展生存时间(PFS)和总生存期(OS)。结果试验组患者疾病控制率为48.4%,对照组为46.8%,两组比较,差异无统计学意义(P>0.05)。两组患者常见不良反应比较,差异无统计学意义(P>0.05)。试验组患者中位PFS为4.1个月,对照组为3.7个月,两组比较,差异无统计学意义(P>0.05)。试验组患者中位OS为7.5个月,对照组为6.9个月,两组比较,差异有统计学意义(P<0.05)。结论二甲双胍联合吉西他滨治疗晚期胰腺癌患者,可提高患者的总生存时间,安全性较好,可推广应用。

Objective To explore the clinical efficacy of metformin combined with gemcitabine in the treatment of advanced pancreatic cancer. Methods Between January 2012 and October 2017,63 patients with advanced pancreatic cancer treated at Wuxi Second People＇s Hospital were selected. Patients treated with metformin combined with gemcitabine or gemcitabine plus cisplatin（ GP） were included in the trial group（ 31 patients）,and patients who were treated with gemcitabine or GP were included in the control group（ 32 patients）. The short-term efficacy including complete remission（ CR）,partial remission（ PR）,stable disease（ SD）,progressed disease（ PD） and adverse reactions were observed and compared. Progression-free survival（ PFS） and overall survival（ OS） were also analyzed and compared. Results The disease control rate was 48. 4% in trial group and 46. 8% in control group（ P〉0. 05）. There was no statistically significant difference in adverse reactions between the two groups（ P〉0. 05）. The median PFS was4. 1 months in trial group and 3. 7 months in control group（ P〉0. 05）. The median OS was 7. 5 months in trial group and 6. 9 months in control group（ P〈0. 05）. Conclusion Metformin is effective in the treatment of advanced pancreatic cancer and has additive efficacy when combined with gemcitabine.